RareCyte
PrivateLast Round
Grant
Aug 21, 2025
Total Funding Raised
$52M
Company Overview
RareCyte operates in Healthcare & Life Sciences and is based in Seattle, Washington. Its latest recorded funding round was a VC Round in June 2024.
RareCyte is a biotechnology company that provides end-to-end platforms for the multiplexed analysis of cells and tissue in research and clinical diagnostics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Precision Medicine, Medical Imaging, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales, Hardware + Subscription, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RareCyte Comparables
Compare RareCyte with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cell Microsystems | 78% | |
| Bruker | 77% | |
| Akoya Biosciences | 76% |
For institutional investors. Book with your work email.
RareCyte Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Aug 21, 2025 | ||||
| VC Round | Jun 27, 2024 | ||||
| VC Round | Sep 9, 2021 | ||||
| Series F | Dec 19, 2019 | ||||
| Series D | Aug 29, 2017 | ||||
VC Round | Aug 22, 2012 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
RareCyte Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Arboretum Ventures | VC Round |
| F-Prime Capital | VC Round |
| The Forest Road Company | VC Round |
| Gates Family Foundation | Grant |
| 5AM Ventures | Series F, VC Round, Series D |
| Logos Capital | VC Round |
| Bill & Melinda Gates Foundation | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 21, 2026
Launched Orion HT and Orion LE systems, expanding spatial proteomics portfolio.
- Apr 21, 2026
Neil Kennedy appointed as the new President.
For institutional investors. Book with your work email.
RareCyte Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about RareCyte's valuation, stock price, and market status.
Is RareCyte a public or private company?
RareCyte is a private company.
What is the current stock price of RareCyte?
RareCyte is a private company, so its shares have no public market price. Caplight tracks RareCyte's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is RareCyte worth (valuation)?
Valuation information for RareCyte is not publicly available.
Can I buy RareCyte stock?
RareCyte shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was RareCyte's last funding round?
RareCyte's most recent funding round was Grant on August 21, 2025.
Who are the main investors in RareCyte?
Key investors in RareCyte include Arboretum Ventures, F-Prime Capital, The Forest Road Company, Gates Family Foundation, 5AM Ventures.
Will RareCyte IPO soon?
No public IPO plans have been announced for RareCyte.
How can I track RareCyte secondary market activity?
Caplight tracks bids, offers, and trades in RareCyte's shares on secondary markets.